Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial.

Leboyer M, Foiselle M, Tchitchek N, Tamouza R, Lorenzon R, Richard JR, Arrouasse R, Le Corvoisier P, Le Dudal K, Vicaut E, Ellul P, Rosenzwajg M, Klatzmann D

Open source

DOI
10.1016/j.bbi.2024.09.005
Published
2025 Jan
Container
Brain, behavior, and immunity
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.bbi.2024.09.005,
  title = {Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial.},
  author = {Leboyer M and Foiselle M and Tchitchek N and Tamouza R and Lorenzon R and Richard JR and Arrouasse R and Le Corvoisier P and Le Dudal K and Vicaut E and Ellul P and Rosenzwajg M and Klatzmann D},
  year = {2025},
  journal = {Brain, behavior, and immunity},
  doi = {10.1016/j.bbi.2024.09.005},
  url = {https://doi.org/10.1016/j.bbi.2024.09.005}
}

RIS

TY  - JOUR
TI  - Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial.
AU  - Leboyer M
AU  - Foiselle M
AU  - Tchitchek N
AU  - Tamouza R
AU  - Lorenzon R
AU  - Richard JR
AU  - Arrouasse R
AU  - Le Corvoisier P
AU  - Le Dudal K
AU  - Vicaut E
AU  - Ellul P
AU  - Rosenzwajg M
AU  - Klatzmann D
PY  - 2025
JO  - Brain, behavior, and immunity
DO  - 10.1016/j.bbi.2024.09.005
UR  - https://doi.org/10.1016/j.bbi.2024.09.005
ER  - 

APA

M, L., M, F., N, T., R, T., R, L., JR, R., R, A., P, L. C., K, L. D., E, V., P, E., M, R., & D, K. (2025). Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial.. Brain, behavior, and immunity. https://doi.org/10.1016/j.bbi.2024.09.005

Source records